These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24400802)

  • 41. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Garwood CL; Hwang JM; Moser LR
    Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery.
    Dobrev D; Goette A; Ravens U
    Cardiovasc Ther; 2009; 27(4):223-5. PubMed ID: 19903184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.
    Anthony CJ; Karim S; Ackroyd-Stolarz S; Fry A; Murphy NG; Christie R; Zed PJ
    Ann Pharmacother; 2011 Jul; 45(7-8):881-7. PubMed ID: 21750309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Limitations of anticoagulant therapy].
    Martí-Fàbregas J; Delgado-Mederos R; Mateo J
    Neurologia; 2012 Mar; 27 Suppl 1():27-32. PubMed ID: 22682207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Alonso-Coello P; Zhou Q; Guyatt G
    Thromb Haemost; 2012 Oct; 108(4):647-53. PubMed ID: 22918481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital.
    Mark L; Dani G; Vendrey R; Paragh G; Katona A
    Med Sci Monit; 2015 Feb; 21():518-25. PubMed ID: 25686556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Warfarin--indications, risks and drug interactions.
    Tadros R; Shakib S
    Aust Fam Physician; 2010 Jul; 39(7):476-9. PubMed ID: 20628660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical practice. Care of patients receiving long-term anticoagulant therapy.
    Schulman S
    N Engl J Med; 2003 Aug; 349(7):675-83. PubMed ID: 12917305
    [No Abstract]   [Full Text] [Related]  

  • 50. Warfarin for stroke prevention in atrial fibrillation: time to switch?
    Ahmad Y; Lip GY
    Int J Clin Pract; 2013 Jul; 67(7):603-5. PubMed ID: 23758442
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel anticoagulants for stroke prevention in atrial fibrillation and chronic kidney disease.
    Turagam MK; Addepally NS; Velagapudi P
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1297-9. PubMed ID: 24138517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.
    Guo Y; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):71-8. PubMed ID: 23466969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?
    Bratland B; Hornnes MB
    Tidsskr Nor Laegeforen; 2014 Jan; 134(2):175-9. PubMed ID: 24477151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.
    Martí-Fàbregas J; Mateo J
    Cerebrovasc Dis; 2009; 27 Suppl 1():111-9. PubMed ID: 19342840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations.
    Lemos Silva R; Carvalho de Sousa J; Calisto C; Braz Nogueira JM; Ravara L
    Rev Port Cardiol; 2007; 26(7-8):769-88. PubMed ID: 17939586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bleeding risks associated with vitamin K antagonists.
    Linkins LA
    Blood Rev; 2013 May; 27(3):111-8. PubMed ID: 23473948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Apixaban and atrial fibrillation: no clear advantage.
    Prescrire Int; 2014 Feb; 23(146):33-6. PubMed ID: 24669381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
    Ezekowitz MD; Wallentin L; Connolly SJ; Parekh A; Chernick MR; Pogue J; Aikens TH; Yang S; Reilly PA; Lip GY; Yusuf S;
    Circulation; 2010 Nov; 122(22):2246-53. PubMed ID: 21147728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Orally active direct thrombin inhibitors.
    Weitz J
    Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.